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ABSTRACT
The human cytochrome P450 enzyme 4X1 (CYP4X1) is among the “orphan” cytochrome P450
meaning there is much unknown about its structure, biological function, and regulation in
literature study. Scientific work on this protein has primarily been on identifying its
physiological functions and expression sites. A recent study found 2 substrates (arachidonic acid
and anandamide) catalyzed by the enzyme. Expression in humans appears to be primarily in the
brain, prostate, lungs, and neurovascular systems and research has linked the protein as a
potential chemotherapy target in brain cancer. So far, only a few inhibitors have been identified.
The goal of this research is to characterize CYP4X1. The first step is to express the protein in E.
coli JM109 cell using either the pCW or pET28a vector. Protein expression attempts indicated
that pET28a vector in JM 109 cells produced a better yield overall. Protein purification was
obtained using cobalt and nickel affinity chromatography made possible by a 6-residue histidine
tag affixed to the protein’s C-terminal following expression. Protein purification is followed by
SDS-PAGE to ascertain purity. Binding affinity assays were obtained for the two previously
published substrates, arachidonic acid, and anandamide. Additional compounds that could be
ligands based on their structural similarity to arachidonic were also assayed. Purified protein was
concentrated and screened with a commercial crystal screen and a crystal hit has been identified
with further optimization required.

KEYWORDS: orphan cytochrome P450, protein expression, chromatographic purification,
binding affinity assays, protein crystallization

iii

EXPRESSION, PURIFICATION AND CHARACTERIZATION OF THE HUMAN
CYTOCHROME P450 ENZYME 4X1 (CYP4X1) USING SUBSTRATE BINDING
AFFINITY, METABOLIC ASSAYS AND PROTEIN CRYSTALLIZATION

By
Olusegun Adeolu Idowu

A Master’s Thesis
Submitted to the Graduate College
Of Missouri State University
In Partial Fulfillment of the Requirements
For the Degree of Master of Science, Chemistry

July 2021

Approved:

Natasha DeVore, Ph. D., Thesis Committee Chair
Gary Meints, Ph. D., Committee Member
Gautam Bhattacharyya, Ph.D., Committee Member
Christopher Lupfer, Ph.D., Committee Member
Julie Masterson, Ph.D., Dean of the Graduate College

In the interest of academic freedom and the principle of free speech, approval of this thesis
indicates the format is acceptable and meets the academic criteria for the discipline as
determined by the faculty that constitute the thesis committee. The content and views expressed
in this thesis are those of the student-scholar and are not endorsed by Missouri State University,
its Graduate College, or its employees.

iv

ACKNOWLEDGEMENTS

I want to deeply thank Dr Natasha DeVore for her unrelenting support, patience, tutelage,
and peaceful demeanor for the entire stretch of this project. She’s indeed a superb human and
honorable supervisor. I would also like to acknowledge my research committee members Dr Gary
Meints, Dr Gautam Bhattacharyya, and Dr Christopher Lupfer for honoring and supporting this
cause with their valuable time and service.
My honorable mention goes to my research colleagues Brenda Wekesa, Mehwish Khokhar
Cody Turner, and friends Polycarp Ofoegbu, Lukio Owuocha, Seth Adu-Amankrah, Ademola
Odusanya, Chideraa Nwachukwu and Adedamola Opalade for the mentoring sessions over the
past 2 years. It was indeed an honor helping with each other’s mental health in graduate school.
What a journey it has been.

I dedicate this thesis to God almighty, my parents and siblings, my jewels of inestimable
value and immense source of encouragement. I love you all.

v

TABLE OF CONTENTS
Chapter 1 – Introduction
Section 1.1 Cytochrome P450

1

Section 1.2 Literature review of enzymatic function (CYP4X1)

3

Section 1.3 Significance of the study

10

Section 1.4 Experimental design

11

Chapter 2 – Materials and methods
Section 2.1 Buffer preparation

14

Section 2.2 Growth media preparation

14

Section 2.3 Cell transformation

15

Section 2.4 Protein expression

16

Section 2.5 Protein harvest

17

Section 2.6 Cell lysis and protein extraction

17

Section 2.7 Centrifugation

18

Section 2.8 Protein purification protocol

18

Section 2.9 Sodium dodecyl-sulfate polyacrylamide gel

20

electrophoresis
Section 2.10 Protein absolute spectrum

23

Section 2.11 Carbon monoxide difference assay

23

Section 2.12 Substrate binding assays

24

Chapter 3 – Results
Section 3.1. Protein expression and purification

25

Section 3.2 Ligand binding assays

55

Section 3.3 Crystal screening for setups

63

Chapter 4 – Discussion and Conclusion
Section 4.1. Discussion

64

Section 4.2. Conclusion

70

References

72
vi

LIST OF TABLES
Table 1. Buffer Preparation

14

Table 2. Summary of protein expressions and purifications

64

vii

LIST OF FIGURES

Figure 1. Cartoon depiction of Cytochrome P450 catalytic activity

1

Figure 2. Illustration of expression and purification of CYP4X1

13

Figure 3. Starter culture for CYP4X1

26

Figure 4. Pelleted cells after harvest, detergent extraction, and lysate on cobalt column

27

Figure 5. UV-VIS spectrum of purified pET28a CYP4X1 protein

27

Figure 6. Electrophoretic gel of pET28a CYP4X1

28

Figure 7. Images of pCW CYP4X1 protein expression process

31

Figure 8. Detergent extraction via Cymal-5 for pCW4X1

31

Figure 9. UV-VIS spectrum of purified pCW CYP4X1 following ion exchange

32

Figure 10. Binding of carbon monoxide to reduced pCW CYP4X1

33

Figure 11. Electrophoretic gel of pCW4X1 with bands near 50 kDa

33

Figure 12. Images from the purification process

36

Figure 13. Absolute protein spectrum from the seventh purification protocol.

37

Figure 14. Carbon Monoxide difference spectrum from the seventh purification.

38

Figure 15. Absolute protein spectrum from CM column

38

Figure 16. Carbon Monoxide difference spectrum from CM column

39

Figure 17. Electrophoretic gel from the seventh purification protocol

39

Figure 18. Pictures from the purification process

40

Figure 19. Absolute protein spectrum of Ni-NTA wash eluate

41

Figure 20. Electrophoretic gel from purification protocol

41

Figure 21. Absolute protein spectrum of Ni-NTA affinity rinse

43

Figure 22. Absolute protein spectrum of Ni-NTA elution for pCW4X1.

45

viii

Figure 23. Absolute protein spectrum of reconcentrated DEAE ion-exchange elution

46

Figure 24. Carbon monoxide difference assay of reconcentrated DEAE elution

46

Figure 25. Electrophoretic gel showing bands for pCW4X1

47

Figure 26. Absolute protein spectrum from DEAE purification

48

Figure 27. Absolute protein spectrum from reconcentrated DEAE purification

49

Figure 28. Electrophoretic gel of 1.9µM pET28a CYP4X1

50

Figure 29. Absolute protein spectrum from pET28a CYP4X1

52

Figure 30 Carbon monoxide difference assay from pET28a CYP4X1

52

Figure 31 Electrophoretic gel of successful 4.1mM CYP4X1

53

Figure 32 Spectrum of arachidonic acid binding assays

56

Figure 33 Saturation curve for arachidonic acid binding assay

57

Figure 34 Saturation curve plot for anandamide binding assay

58

Figure 35 Spectrum of anandamide binding assay

58

Figure 36 Saturation curve plots for ketoconazole binding assay

59

Figure 37 Spectrum of ketoconazole binding assay

60

Figure 38 Spectrum of eicosapentenoic binding assay

61

Figure 39 Spectrum of PEITC Binding Assay

62

Figure 40 Crystals of CYP4X1

62

ix

CHAPTER 1 - INTRODUCTION

1.1 Cytochrome P450
Cytochromes P450 depicted in Figure 1 is a family of enzymes that have heme as a
cofactor and function as monooxygenases. Monooxygenases are enzymes that catalyzes
oxidation reactions by adding one atom of oxygen to a substrate, typically as a hydroxyl, through
oxidation reactions that give water, NADP+ and hydroxyl of the organic substrate as the
products.

Figure 1: Cartoon depiction of Cytochrome P450 catalytic activity. This reproduced image was
made by Natasha DeVore Ph.D., BY CC-SA 4.0, image not modified.

Cytochrome P450 (CYP450) catalytic activity is a membrane bound oxidation of
numerous biologically active substrates in a stepwise series of electron transfer reaction starting
with nicotinamide adenine dinucleotide phosphate (NADPH). CYP450 requires an additional
redox partner in form of CYP450 reductase (POR) that aids in the electron transfer process by
1

accepting and transferring two electrons that makes the actual CYP450 enzyme catalytically
active. (Waskell & Kim, 2015). There is also the needed requirement of both atomic oxygen and
NADPH to effect a reaction. NADPH transfers single electrons via hydride ions to flavin adenine
dinucleotide (FAD) and then to flavin mononucleotide (FMN). This electron is then used in the
conversion of a lipophilic substrate to a hydroxy metabolite and water as by product in
endoplasmic reticulum. (Waskell & Kim, 2015).
In humans, the cytochrome P450 enzymes are mainly located in the liver and are
membrane-associated proteins found in the inner membranes of mitochondria or the endoplasmic
reticulum. Nonetheless, the cytochrome subfamilies, CYP4A, CYP4B, CYP4F, CYP4V,
CYP4X, and CYP4Z, are present in most body tissues. (Kumar, 2015).
Cytochrome P450s are involved in the oxidation of fatty acids, steroids, xenobiotics, and
the synthesis and breakdown of hormones (Hsu, Savas, Griffin & Johnson, 2007). The
cytochrome P450 family is also involved in the removal of xenobiotics, different components of
drugs and environmental chemicals, clearance of vitamins, and oxidation of eicosanoids (Stark &
Guengerich, 2007). CYP450 may also have a role in immune responses through metabolic
modification and regulating eicosanoid concentrations during inflammation (Kalsotra & Strobel,
2006).

There are 54 other cytochrome P450s found in humans. However, not all functions of
each specific cytochrome P450 are known, Including cytochrome P450 enzyme 4X1 (CYP4X1).
CYP4X1 is currently classified as an orphan cytochrome P450, meaning there is still a lot
unknown about its structure and function. Only limited studies have been conducted with
purified CYP4X1 enzyme. Thus, the expression, purification, and characterization of the
CYP4X1 enzyme is our goal to understand the biological role of CYP4X1 better. The
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characterization of purified CYP4X1 can be carried out using binding affinity and metabolic
assays.

1.2 Literature Review of Enzymatic Function (CYP4X1)
CYP4X1 gene is expressed in the brain (Kharkwal et al., 2017). The CYP4X1 protein on
the other hand is present in various tissues in the human body, including the skeletal muscles,
trachea, and aorta. (Al-Anizy et al., 2006; Stark, Dostalek & Guengerich, 2008).
Indeed, an original study conducted by Bylund, Zhang & Harder, (2002) first identified a
unique CYP450 isoform with localization in the brain. This novel cytochrome was identified
from orthologous cDNA cloning via reverse transcription-PCR from brain samples of rats. This
was the first time the protein was elucidated, and the deduced amino acid sequence exhibited
amino acid identity of around 41% - 51% with that of members of the rat CYP4 subfamilies
(Bylund, Zhang & Harder, 2002).
The study conducted by Bylund, Zhang & Harder, (2002) used the northern blot to show
that the isoform CYP4X1 is highly expressed in the brain. In situ hybridization indicated that it
was mainly expressed in different brain regions, such as the cortex, hippocampus, cerebellum,
and brain stem, an indication that it may be involved in critical physiological processes (Bylund
et al., 2002).
Bylund, Zhang & Harder, (2002) study referenced that CYP4 family is known to be
mainly involved in omega hydroxylation of fatty acids like. Also, a more recent evolutionary
relationship study by Kirschian & Wilson (2012) determined for CYP4 subfamilies hypothesized
that the CYP4X1 is specialized in the metabolism of long-chain fatty acids (e.g., arachidonic
acid). The enzyme was identified from EST database as a member of the CYP4X and the human
isoform was ultimately designated as CYP4X1 (Bylund, Zhang & Harder, 2002). The human
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CYP4X1 gene is found within the P450 ABXZ gene cluster on the first chromosome and is
comprised of 509 amino acids. However, the functions of the CYP4X1 cytochrome are mostly
unknown, and as such, it is referred to as an ‘orphan’ cytochrome. (Bylund, Zhang & Harder,
2002).
Similarly, Al-Anizy et al. (2006) showed that the CYP4X1 was principally expressed in
the brain and aorta of a mouse model. This was accomplished by using cDNA of the mouse via
cloned brain RNA sequence (94% identity); to detect antibodies specifically developed for
CYP4X1. The study used the northern blotting technique by using antibodies against modified
nucleosides to establish that CYP4XI was expressed in the brain.
Different studies that have been conducted have shown that CYP4X1 might be involved
in tumorigenesis, as the expression in cancer cells has been noted to be high (Al-Anizy et al.,
2006). Murray, Patimalla, Stewart, Miller & Heys, (2010) conducted a study on the expression of
the P450 system in breast cancer cells and their influence on tumor development. In the study, a
tissue microarray containing 170 breast cancers was immuno-stained to test out 21 P450
antibodies (CYP4X1 inclusive) via histochemistry. Histochemistry is a biochemical technique
that enables the identification of pivotal structures in tissues when stained and viewed under the
microscope. The degree of immuno-stained tissues via the distribution of chemical components
was determined and used to show the varying levels of CYP450 expressions. The results showed
that the cytochrome P450 expression was high, and the levels varied within the subfamilies.
Overall, the study by Murray, Patimalla, Stewart, Miller & Heys, (2010) showed that the
strongest immunopositivity for breast cancer were highest in percentage at 50.8% for CYP4X1.
Figures indicate that CYP variants are actively involved in the metabolism of anticancer drugs
targeted for breast cancer. Therefore, the study concluded that the expression of the
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monooxygenase enzymes (CYP450s) in the cancer cells was high, which could potentially be
tied to down regulation by metabolizing a therapeutic drug that might help target cancer (Hsu,
Savas, Griffin & Johnson, 2007).
In another study, Wang et al. (2018) noted that CYP4XI might be involved in human
glioma vasculature. The experiment tested the ability of a novel flavonoid 2’-OMethylhelichrysetin (CH625) to inhibit CYP4XI in tumor-associated macrophages (TAM). Their
study showed that CH625 inhibition of CYP4XI caused vasculature normalization leading to
improved survival of glioblastoma in rats. Furthermore, the findings indicated that the inhibition
by CH625 occurred through the downregulation of vascular endothelial growth factor (VEGF)
derived from Tumor-associated macrophages (Wang et al., 2018). Also, the cannabinoid
receptors type 11 (CB2) helped in the expression of specific tumor growth factor and activated
epidermal growth factor receptor (EGFR) and downstream signal transducer and activator of
transcription 3 (STAT3), which are vital in tumor therapy (Wang et al., 2018). In vitro, TAM
polarization increased T-cell proliferation and the migration of pericytes, reduced the production
of VEGF and transforming growth factor beta (TGF-β), and downregulated the expression of
cannabinoid receptors and EGFR (Wang et al., 2018). However, the overexpression of the
CYP4X1 and the STAT3 led to the reversal of these effects that were noted after the polarization
of TAM, an indication that CYP4X1 is involved in the normalization of the glioma vasculature
(Wang et al., 2018). Inhibition of the CYP4X1 by the flavonoid CH625 also led to the delayed
growth and prolonged survival of the affected rats.
In an earlier study, Carmeliet & Jain, (2011) showed that the proliferation and movement
of endothelial cells led to the production of immature tumor vessels with low perfusion and
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oxygenation thereby inhibiting the survival of glioblastoma cells. This research by Wang et al.
(2018) shows promise for the clinical use of inhibitors for CYP4X1.
In another study, Stark, Dostalek & Guengerich (2008) determined the expression in
mammalian cells and purification of the CYP4X1 in bacteria. The real-time PCR analysis
indicated the protein expression in mRNA in extrahepatic tissues, liver, heart, prostate, breast,
and human brain structures such as the amygdala, basal ganglia, and cerebellum (Stark, Dostalek
& Guengerich, 2008). The substrate used in the experiment was anandamide. A quantitative
Polymerase Chain Reaction was used to indicate the cytochrome levels in mRNA of the brain.
The results showed that the levels of CYP4X1 expression were high in the brain (Stark, Dostalek
& Guengerich, 2008). The researchers concluded that the CYP4X1 gene might have a role in the
signaling of the brain, cardiovascular functions, and mediation of signaling in the neurological
and immune systems due to the high expression in the amygdala and the distribution patterns.
The expression patterns of the CYP4X1 gene in blood vessels and specific brain regions
might indicate that it has a neurovascular role (Al-Anizy et al., 2006). The neurovascular
function may be related to the metabolism of arachidonic acid, which is involved in regulating
cerebral blood flow (Davis, Liu, & Alkayed, 2017). Arachidonic acid is an essential fatty acid
involved in the mediation of inflammation during immune system responses (Tallima & El Ridi,
2018). It has also been noted to have a role in other physiological processes, including
mitogenesis, activation of calcium ion-dependent potassium ion channels in cells, vasodilation,
and regulating the blood pressure and cellular levels of ions (Stark, Dostalek & Guengerich,
2008).
Derivatives of arachidonic acid such as anandamide and eicosanoids have often been
implicated in physiological processes such as mediation of cell signaling, development of
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immune reactions, and cardiovascular functions. Cytochrome P450 enzymes can also modify
these derivatives (Stark, Dostalek & Guengerich, 2008). The anandamide binds to a cannabinoid
receptor as it is an endogenous cannabinoid receptor ligand (Stark, Dostalek & Guengerich,
2008). At high concentrations, studies have shown that the anandamide is an agonist of vanilloid
receptor-1 mediated functional responses such as the vasodilation of small arteries and the
development of inflammatory and acute pain signals (Stark, Dostalek & Guengerich, 2008; Ross,
2003).
Binding assays can be used to determine the substrate affinity of a ligand for a protein.
The binding affinity of arachidonic acid and anandamide to CYP4X1 is not known. Different
assays have explored the binding affinities of various fatty acids to other membrane bound
catalytic enzymes.
Different studies have been carried out to understand the structure and function of
CYP4X1. For instance, Kumar (2015) developed a homology model using Modeller 9v8 to
identify the binding site of CYP4X1 and demonstrate the topology of the active site. Different
programs were used to assess the protein’s energy stability, its geometrical errors, and structural
validation. The model was then used for molecular docking of the fatty acid and its derivative;
namely arachidonic acid and anandamide respectively (Kumar, 2015).
The results obtained by Kumar (2015) suggests that various amino acid residues,
including threonine 312, phenylalanine 491, alanine 126, serine 251, and asparagine 319, were
involved in the interaction of arachidonic with the CYP4X1. Also, they showed that the
interaction of arachidonic acid derivative, anandamide, was aided by amino acid residues such as
leucine 315, serine 251, alanine 126, phenylalanine 491, and proline 118 (Kumar, 2015). These
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amino acid residues influence the Cytochrome P450 system's catalytic activity and can be used
as candidates for mutagenesis to further test the importance of the residues (Kumar, 2015).
Furthermore, Kumar (2015) studied arachidonic acid and anandamide using the Lipinski
rule drug-likeness test to demonstrate their effectiveness as orally active compounds. The
Lipinski rule is an industry adopted rule of thumb that entails 5 medicinal chemistry criteria
required during drug discovery, research, and testing. These 5 parameters range from molecular
weights, partition coefficient, hydrogen bond acceptors and donors etc. Kumar (2015) concluded
that the binding of arachidonic acid to the cytochrome P450 system required the action of key
amino residues on the CYP4X1 polypeptide sequence. However, the acid's binding was stronger
at −7.76kcal/mol than that of its derivative at −5.76 kcal/mol. Both arachidonic acid and
anandamide predicted anti-carcinogenic activity based on reported biological spectrum data and
the potential of being used as a drug target for cancer therapy (Kumar, 2015). Kumar (2015)
study was useful in indicating the roles that the CYP4X1 system might be involved in and
provided a model of its structure.
Similarly, the review by Davis, Liu & Alkayed (2017) showed that CYP4X1 might have
a role in the maintenance of neurovascular homeostasis and cell signaling. Stark, Dostalek &
Guengerich (2008) indicates that CYP4X1 may be involved in cardiovascular functions were
further supported by a study by Carver, Lourim, Tryba, & Harder, (2014). Carver, Lourim,
Tryba, & Harder, (2014) demonstrated that there is a circadian regulation of the expression of
CYP4X1 gene. However, the overall cause of circadian changes in blood flow is unknown
(Carver, Lourim, Tryba, & Harder, 2014). CYP4X1 oxidizes arachidonic acid in its expression
sites (brain and vascular systems) to yield epoxyeicosatrienoic acids (EETs) (Stark, Dostalek &
Guengerich, 2008). EETs induce an associated blood flow increase via vasodilation (Carver,
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Lourim, Tryba, & Harder, 2014). Given the role of CYP4X1 in the cardiovascular system,
Carver, Lourim, Tryba, & Harder, (2014) study suggests that the presence of arachidonic acid
may influence circadian changes in blood flow by testing if the EETs obtained from the
oxidation of arachidonic acid vary in a circadian manner. Carver, Lourim, Tryba, & Harder,
(2014) experiments were inconclusive and requires further studies. Also, it is noteworthy that
Snider, Kornilov, Kent, & Hollenberg, (2007) demonstrated that cytochrome P450s had
negligible action in oxidizing anandamide.
Kharkwal et al., (2017) carried out a study to determine the effects of CYP4X1 in the
metabolism of energy and the impacts of the bodyweight of mice. The study investigated
whether the action of the CYP4X1 influences the endocannabinoid signaling systems that affect
energy metabolism and appetite. The endocannabinoid system is an intercellular signaling
system with a role in the homeostasis of energy by matching the intake of calories and energy
use (Cristino, Becker, & DiMarzo, 2014).
In a Kharkwal et al. (2017) study, transgenic knockout mice were developed. Their total
mRNA in different organs like the brain, heart, skin, kidney, colon, lungs, aorta, and liver were
quantified through PCR and spectrophotometry. The body weight effects of food intake on mice
were recorded and evaluated after a standard rodent and high fat diet was provided for some
weeks (Kharkwal et al., 2017). The mice were then monitored comprehensively and tested for
blood and glucose tolerance. Also, the net weight of the epididymal fat pads of the knockout and
control mice were determined (Kharkwal et al., 2017). The results showed that CYP4X1
knockout mice had more bodyweight than the control mice with similar genetic backgrounds
(Kharkwal et al., 2017). Also, the knockout mice had more intra-abdominal fat deposits and
enlarged adipocytes.
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The results obtained by Kharkwal et al. (2017) also showed differences in the respiratory
exchange ratio (RER) in the mice. RER is basically the volume ratio between the carbon dioxide
produced and the oxygen used by the body. Vco2/Vo2 can be used in estimating which fuel
(carbohydrate or fat) is being metabolized during rest or mild aerobic activities. This is a
biomarker for respiratory fitness and the amount of adipocyte present. The knockout mice had a
reduced RER than the control mice (Kharkwal et al., 2017). The low exchange ratio in mice with
high adiposity levels was consistent with the results of studies showing that increased adiposity
is associated with a high degree of fat oxidation that negatively affects the respiration system.
Kharkwal et al. (2017) concluded that CYP4X1 has a role in regulating fat metabolism and the
influence of appetite.

1.3 Significance of the Study
CYP4X1 is an orphan cytochrome as its functions in endogenous and exogenous
metabolism have not been entirely documented. Only limited studies have been conducted with
purified CYP4X1 enzyme. The location of the gene and its variants in the human genome are
well established. There is also some evidence that CYP4X1 may be involved in physiological
roles such as inflammation. However, significant knowledge about the exact placement of
CYP4X1’s role in these processes is unknown. The CYP4X1 gene has been expressed using real
time PCR analysis in different organs in the human body, such as the brain, heart, prostate skin,
breast, and liver (Stark, Dostalek & Guengerich, 2008).
Although arachidonic acid and anandamide have both been identified as substrates, the
substrate turnover is not at a rate consistent for a typical cytochrome P450 with endogenous
substrates (high nM or very low µM Km range). Studies have shown that the binding of identified
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substrates is aided by various amino acids that influence their catalytic activity (Kumar 2015).
Both arachidonic acid and anandamide are involved in multiple physiological functions,
including mitogenesis, vasodilation, blood pressure regulation, and cellular ion levels. (Tallima
& El Ridi, 2018; Snider, Kornilov, Kent & Hollenberg, 2007). Since it is involved in the
oxidation of arachidonic acid, the cytochrome P450 system is thought to have a direct role in
these physiological processes. However, it is also possible that CYP4X1’s involvement is due to
the metabolism of an alternative yet unidentified substrate.

1.4 Experimental Design
This study involved the expression, purification, and characterization of CYP4X1 to
investigate its binding affinity with ligands. This was accomplished by adopting similar best
practices from advances and failures on recombinant protein expression in Escherichia coli by
(Rosano & Ceccarelli, 2014).
A bacterial plasmid (pET28a) and cloned vector (pCW) was used to express the gene in
Escherichia coli bacteria JM109 cells. CYP4X1 purification was conducted using Ni-NTA
(nickel beads) and cobalt affinity column chromatography, a technique made possible by a 6residue histidine tag cloned in sequence with the CYP4X1 gene in the plasmid.
This step was followed by Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
(SDS–PAGE) to ascertain protein purity following the purification. The technique entailed using
Coomassie blue stain to detect bands containing as low as 100 nanograms of protein rapidly
(Raynal, Lenormand, Baron, Hoos & England, 2014). UV-VIS spectrophotometry was used to
confirm the purity and to quantify the concentration of CYP4X1 based on the absorbance of the
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heme which is specific for that obtained CYP4X1 (Raynal, Lenormand, Baron, Hoos & England,
2014). UV-VIS spectrophotometry is a useful approach for detecting non-protein contaminants.
Ligand binding affinity assay tests with purified CYP4X1 to further characterize the two
known substrates and potentially identify other substrates was keenly pursued. Trying out other
potential substrate. A more recent study by Pal et al. (2020) for example revealed that the
binding affinity of eicosapentaenoic acid and docosahexaenoic acid could be shown by
competing for residency with membrane phospholipids (Pal et al., 2020). And perhaps proteins.
Lastly, a crystal screen is performed to determine the crystallization condition of
CYP4X1 after the protein optimally purified. The method was designed to provide a highly
effective and rapid screening for biological molecules (Wooh, Kidd, Martin & Kobe, 2003). The
screens have helped find the initial crystallization conditions for more than 1,000 proteins,
peptides, oligonucleotides, and small molecules (Wooh, Kidd, Martin & Kobe, 2003). It uses the
features of a sparse matrix screen that effectively sample polymers, salts, pH, and organics.
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CHAPTER 2 - MATERIALS AND METHODS

Proteins are ubiquitous in living systems and play diverse and pivotal roles that is
essential to sustain life. Yet, proteins especially those associated with membranes are delicate,
finicky, and quite painstaking to elucidate in research which in turn affects obtainable yield. In
this project, both the materials and methods used were established and adopted from published
literature (DeVore et al., 2011). The methodology was optimized during multiple expression
attempts and purification trials. The protocols leading to CYP4X1 characterization followed a
sequential method illustrated in Figure 2 and as follows; cell transformation, protein expression,
cell harvest and lysis, protein extraction via proprietary detergent, purification using cobalt,
nickel-nitriloacetic acid (Ni-NTA), carboxymethyl (CM) and Diethylaminomethyl (DEAE)
beads, assertion of protein purity via SDS-PAGE and characterization using ligand binding
assays.

Figure 2. Illustration of expression and purification of CYP4X1. Reproduced from website
<https://www.profacgen.com/recombinant-protein-expression-in-ecoli.htm (Accessed
6/22/2021). Images not modified.
13

Purified protein was also used to screen for crystallization condition for CYP4X1. Thus, in this
chapter, the steps and associated material used were discussed in detail.

2.1 Buffer Preparation
Buffers are solutions specially prepared to prevent pH imbalance that could adversely
affect functionality of an active protein. The buffers and the recipe used to make them are listed
in Table 1.

Table 1: Buffers used for affinity chromatography and ion exchange chromatography.
Buffer Name
Tris Buffer Glycerol
Water
NaCl Imidazole
(mM)
(mL)
(mL)
(mM) (mM)
Resuspension Buffer

500

50

200

300

N/A

Ni-NTA Wash Buffer

50

50

400

50

10

Ni-NTA Elution Buffer

100

50

400

50

100

Ion Exchange Wash Buffer

50

50

425

N/A

N/A

Ion Exchange Elution Buffer

100

50

400

500

N/A

2.2 Growth Media Preparation
Growth media is prepared prior to the start of protein expression of desired cellular
protein. This serves as a source of nutrient for the increase and maintenance of the recombinant
Escherichia Coli strain. The creation of optimal growth environment needed by bacterial cells
during replication is principal to successful protein expression.
2.2.1 Lysogenic broth (LB Media). 1g tryptone, 1 g sodium chloride, 0.5 g yeast extract,
4ml glycerol. The reagents are added into a 150 ml conical flask and partially dissolved with
100ml of water. The resulting solution is covered in aluminum foil and earmarked at the top with
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autoclave tape. LB media is autoclaved for 15 minutes at 15 psi and 121-124°C for sterility.
Lysogenic broth was used as growth medium for inoculating starter culture.
2.2.2 Terrific broth (TB Media). 50.8g terrific broth powder, 4ml glycerol, 900 ml
water to make 1 Liter of terrific broth in a 2-litre conical flask. The broth was autoclaved after
mixing components together. Terrific broth was used for cell growth scale up. The medium is
suitable for both selective and non-selective cultivation of E. coli strains for cloning and higher
density yield production of recombinant proteins. As is the case for the method used, selective
cultivation is possible when appropriate antibiotics are added to prevent the growth of other
microbes.

2.3 Cell Transformation
The CYP4X1 gene carries the encoded instruction that is translated into the desired
protein required for characterization. To express CYP4X1 gene into a functional heme protein of
E. coli JM109 cells, it starts with bacterial cell transformation using heat shock technique. Cell
transformation via heat shock enables cell exposure to sudden temperature increase which
creates an osmotic pressure difference that induces the formation of pores favorable for the
uptake of DNA plasmid or cloned vector. Attenuated E. coli JM109 cell strain stored in glycerol
at -80°C is placed on an ice bed to thaw. One microliter of purchased plasmid (pET28a) or
cloned vector (pCW) carrying the gene that encodes for CYP4X1 protein is aliquot into thawed
E. coli JM109 cells. The vector and bacteria cells were mixed in an Eppendorf tube and the
resultant mixture was placed on ice for 30 minutes. The Eppendorf tube mixture is removed and
concurrently placed in 37°C water for 35 seconds. The tube content was aliquot into culture
plates containing agar using a micropipette. Then, silica beads were used to spread content across
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the entire culture plate. For optimal bacterial growth, the culture plate is placed in an incubator
overnight at 37°C.

2.4 Protein Expression
Protein expression in this research was achieved via pET28a plasmid and cloned vector
(pCW). To do this, 10 ul of glycerol stock or a single colony of transformed JM109 cells is
picked with a micropipette and inoculated into 100ml of autoclaved lysogenic broth (LB media).
This is followed by the addition of 100 ul of 50mg/ml antibiotic stock (kanamycin sulfate or
ampicillin) to LB media; The antibiotic stock helps prevent the growth of unwanted microbes
and ensures that only transformed JM109 cells grow. The E. coli immunity to the applied
antibiotic has been encoded as information (nucleotide sequence) during gene construct.
The resulting mixture (starter culture) is placed in a shaking incubator all night at 180 rpm and
37°C. An observation of cloudy starter culture the next day signifies bacterial growth. The
starter culture is scaled up for optimal bacterial cell growth by adding it in fractions into 2-3
liters volumetric flasks of TB media. This step is quickly followed by the re-addition of 1ml of
50mg/ml of kanamycin or ampicillin to each 1-liter flask containing TB media depending on the
vector used. Allowing for peak logarithmic growth, the cell cultures are placed in a shaking
incubator at 37°C for 2 hours 30 mins and/or until an absorbance range between 0.8 - 1.4 at 600
nm wavelength (OD600) is attained.
To induce optimal growth of the targeted heme protein in the bacterial cells, 0.22 g/l each
of Isopropyl β-D-1-thiogalactopyranoside (IPTG) and Aminolevulinic acid (ALA) is added to
the cell cultures after absorbance check. This was done by adding 0.48 g of ALA and 0.96 of
IPTG to 2ml of distilled water. ALA is a precursor for the formation of the heme group and
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IPTG helps to induce ample growth of the targeted protein. The reagent powder was mixed and
vortexed into a solution. To initiate expression of desired heme protein, 1 ml of the resulting
solution was aliquot to each 1-liter flask making up 3-liter cultures total. Lastly, the 2-liter
cultures are subjected to decreased growth temperature of 32°C and then placed in the shaking
incubator for 2-3 days.

2.5 Protein Harvest
CYP4X1 protein is harvested by collecting aggregated pellet of bacterial cells. This is
achieved by aliquoting optimally grown E. coli JM 109 cells into centrifuge tubes to spin at 4200
rpm for 15 mins. Cell pellets showing requisite heme-thiolate reddish brown coloration are
collected after centrifugation and solubilized in resuspension buffer while the supernatant is
discarded by adding bleach. Cell pellets in resuspension buffer are stored at -80°C or
immediately deployed for the next phase, which is cell lysis and membrane protein extraction.

2.6 Cell Lysis and Protein Extraction
Extraction of intracellular membrane proteins initially requires cell lysis which basically
is the breaking apart of the phospholipid bilayer for accessibility. This process involves a
combined use of sonication (a form of mechanical disruption) and application of detergents. To
accomplish this for my project; frozen E. coli JM109 cells solubilized in resuspension buffer
which contains the membrane heme protein CYP4X1 is thawed at room temperature water for
about 20 mins. The thawed sample is sonicated on an ice bed 3 times for 30 seconds whilst
waiting 30 seconds interval between each ultrasound exposure. Once the cells are lysed, Cymal-5
is added to the sample, then the cell pellets are stirred on an ice bed for 1 hour using a magnetic
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stirrer. This helps to solubilize the proteins of interest, making it easier to extract hard to reach
membrane protein. To calculate the amount of Cymal-5 added to enable protein extraction is as
follows:
3.2 mM x ____ mL sample x 494.5 g/mol = ______/1000/1000 = _________ g Cymal-5.
The 3.2 mM of Cymal-5 is based on the critical micelle concentration, that is the lowest
concentration where micelle formation will occur. 494.5g/mol is the molecular weight of Cymal5. The subsequent divisions by a thousand (twice) is to adjust for S.I unit conversions from
millimolar to molar and from milliliter to liter respectively.

2.7 Centrifugation
Utilizing centrifugal force to separate proteins based on their physical properties like
solubility, size, shape, density is commonplace in bioanalytical chemistry. Centrifugation was
first used to harvest cell pellets after 48 hours of scaled-up growth. Also, after solubilizing target
membrane protein using Cymal-5 in the extraction phase. The resulting solution is cold
centrifuged at 15000 rpm for 20 mins to isolate solubilized protein. Soluble liquid heme protein
(lysate) is saved for purification via affinity and ion-exchange column chromatography while the
cell pellet is discarded after adding bleach.

2.8 Protein Purification Protocol
Purification method used was low pressure liquid chromatography. Chromatography
techniques separate mixtures based on interaction and speed at which the components move
through special media contained in a matrix. In principle, low liquid pressure was used to move
sample (protein) mixture through a packed stationary phase column affixed with specialized
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material (Ni-NTA, Cobalt, CM and DEAE). The mobile phase solvent was set up with buffers
indicated in the buffer table (Table 1) and liquid protein mixture; to be separated based on their
characteristic interaction with the stationary phase material while eluting into a fraction collector
using differential buffer environment and/or retention times.
Resuspension buffer and wash buffer used for this research had negligible interference
with the sample to be separated because the pH (7.4) of the buffer is lower than the isoelectric
point, pI (8.3) of the protein. The value difference has to be ensured or else, the surfaces of the
protein will be largely negatively charged instead of neutral. Thus, repelling each other. Ensuring
optimum pI is essential to the aggregation of protein in buffer solution.
Elution buffer on the other hand contains imidazole which helps to detach the binding of
column matrix (cobalt or nickel) with the six-residue histidine tagged protein. Also, Cymal-5
was added to the buffers at some point in the research as a form of adaptation to methodology
during experimental troubleshooting. Cymal-5 amphiphilic properties enables an interaction
between its hydrophilic end and the hydrophobic membrane protein. Thus, keeping the protein
soluble outside their core phospholipid bilayer.
2.8.1 Preparing column and mobile phase. The extraction lysate after centrifugation
during was subjected to affinity column chromatography using cobalt or Ni-NTA (Nickel
charged affinity resin). This was done by first setting up the stationary phase column with for
example, 5ml of Ni-NTA beads contained in a slurry of buffer. The lysate is then added to the
column. Then, the mobile phase is set up starting with resuspension buffer, followed by wash
buffer and then elution buffer. Before purification begins, the slurry of buffer is allowed to flow
through the column, then resuspension buffer is running through the aa beads into the fraction
collector using a Bio-Rad biologic LP chromatography. The procedure for loading lysate,
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rinsing, washing, and eluting the protein of interest was programmed alongside the allocation
volume and the timeline prior to start of the purification protocol. Flow through is collected
during the column purification process by a fraction collector.
2.8.2 Loading protein sample on beads. Soluble liquid CYP4X1 protein is suctioned
onto the Ni-NTA (nickel beads) by the Bio-Rad Biologic LP chromatograph. The beads turn red
as the heme-thiolate protein binds. This was made possible by the 6-residue histidine tag affixed
to the protein during Protein expression.
A 100 ul fraction of the heme protein solution that flows through is collected into an Eppendorf
tube and labelled ‘’Flow-through’’). 20 mL re-suspension buffer is added to the column.
2.8.3 Wash the beads. 20 ml of wash buffer is suctioned into the column and passed
through the Ni-NTA beads. The wash buffer contains a low concentration of imidazole to
remove weakly binding proteins.
2.8.4 Elute the protein. Protein is eluted from the column by adding 30 mL of elution
buffer which contains high concentration of imidazole to remove all protein bound to the
column.

2.9 SDS Poly Acrylamide Gel Electrophoresis (SDS-PAGE)
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is used to
separate proteins based on their molecular weight through a specialized gel matrix. SDS-PAGE
helps to ascertain the presence and purity of the CYP4X1. The SDS part contains an anionic
detergent carrying negative charges which is used to invalidate the intrinsic positive charges of
the proteins thereby giving them equivalent charge and mobility in an electric field. Another
reagent β-mercaptoethanol (BME), a thiol-reducing agent included in the sample preparation step

20

helps to denature the three-dimensional structure of the protein. The denatured protein(s) is/are
attracted and move towards an applied electric field based on their mass-to-charge ratio. Thus,
smaller proteins migrate faster through the gel matrix due to less resistance in moving through
the porous layers. The presence of Cytochrome P450 protein (CYP4X1) is a horizontal band
around 50kDa which is obtainable across the collected affinity chromatography fractions namely,
flowthrough, rinse, wash, and elution.
To accomplish this, a Bio-Rad gel is obtained from refrigerated storage and used to set up
the gel apparatus in the inner compartment of an electrophoretic box. The refrigerated gel and the
gel dam are put together into a clamped frame or sealed gasket forming the inner compartment,
the inner compartment is then secured in a casting gel-box stand. If properly done, the entire setup should be leak-proof. Electrophoretic buffers are poured until they overflow on the inside
chamber, as well as a marked buffer limit on the outside compartment. After the gel apparatus is
fully assembled, a plastic comb atop the anionic gel is gently removed. The samples are added
into the gel wells in a stepwise fashion using a micropipette with specialized tip; Firstly, a
protein ladder containing pre-stained molecular weight marker is added to well number 1; this is
followed by the chromatographic eluates in the order of flowthrough, rinse, wash, and elution.
The protein ladder enables the estimation of the molecular weight region for a variety of protein
standards.
2.9.1 SDS-PAGE buffer and solution recipes. Coomassie Staining Solution: To make a
100 ml Coomassie staining solution, 0.25g of Coomassie brilliant blue R250 is added to a
Wheaton bottle, then 10 ml of glacial acetic acid is added to the mixture. Finally, 90ml of EtOH:
H2O (1:1 v/v) is added and mixed well.
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SDS-PAGE 10x Electrophoresis Buffer:
10x electrophoresis buffer comprises of: 25mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3.
To make this, 30 g of Tris base, 144 g of glycine, and 10 g of sodium dodecyl sulfate is dissolved
in 950 ml of H2O. The solution is made up to the 1000 ml mark. The pH of the buffer should be
8.3 with no adjustment required.
SDS-PAGE 1x Running Buffer:
Prepare 500 mL of 1x SDS-Page running buffer by adding 50 mL of 10X SDS-PAGE
electrophoretic buffer to 450 mL of diH2O.
2.9.2. SDS-PAGE sample preparation. Aliquot 10 ul of protein ladder into
appropriately labelled Eppendorf tubes. Add 10 ul β-mercaptoethanol (BME) into ladder to
achieve a final volume of 20 ul and concentration of 0.55M, mix well on shaker for uniformity.
Repeat above protocol on the other eluates in the order of flowthrough, rinse, wash, and elution.
Take note of the gel well numbers viz-a-viz sample descriptions, concentrations and loaded
volumes.
2.9.3. SDS-PAGE protocol. Aliquot 10ul of sample mixture into gel wells starting with
the protein ladder. Cover the chamber and firmly connect both the anode and the cathode. Set the
voltage on the electrophoresis power supply to a constant voltage of 210 and turn on the
instrument run. Allow the gel to electrophorese for 45–90 minutes or till the dye front gets to the
bottom of the gel plate. Then the device power is turned off. Disconnect the electrodes and
remove the cover. Remove gel holder from the electrophoresis chamber. Carefully remove the
gel from holder. Remove the gel from its plates and proceed to staining with Coomassie blue.
Coomassie blue staining and rinsing is done 3-4 times all whilst warming it up briefly in the
microwave oven at intervals for 30 secs.
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2.10 Protein Absolute Spectrum
Purified protein fraction eluted from Ni-NTA affinity low pressure liquid
chromatography is subjected to UV-VIS spectrophotometry. Herein, Beer-Lambert’s equation is
applied to quantify the amount (concentration) of CYP4X1 based on the absorbance of the heme
which is specific for CYP4X1. This is done by baselining and autozeroing the UV-VIS set at
wavelength of 750nm – 250nm with Elution/Wash Buffer. Thereafter, 750mL of eluted protein
fraction is placed in a cuvette at the wavelength range and ran for absorbance. The concentration
of the obtained protein is then calculated by applying the Beer-Lambert’s equation of A = ϵCl.
Where A = Absorbance
C = Concentration

ϵ = Molar Absorptivity Constant where 0.1 µM-1cm-1 is the heme coefficient
l = Path Length.

2.11 Carbon Monoxide Difference Assay
The carbon monoxide (CO) difference assay tests for the active functionality of protein
using UV-VIS spectrophotometer. An elevated shift in spectra to the right to 450 nm in
comparison to the absolute spectrum which has a heme peak at ~ 410 nm is indicative of an
active CYP450 protein. To accomplish this, the UV-VIS wavelength scan is set to between 500
nm to 350 nm. Then, 750µL of CYP4X1 fraction is placed into a cuvette. Sodium dithionite is
added to the fraction as a reducing agent. The cuvettes containing the fraction are placed in the
UV-VIS. The instrument is autozeroed and baselined with the reduced fraction. Then, we bubble
50 carbon monoxide bubbles into it. Afterwards, we take and observe the spectra for an elevated
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right shift. The amount of active protein can then be quantified by Beer-Lambert’s equation as
described above. The molar absorptivity constant for CO bound heme is 0.091 µM -1cm-1.

2.12 Ligand Binding Assay
Ligand binding assays conducted evaluates the affinity of substrates like arachidonic
acid, anandamide, eicosapentaenoic acid, docosahexaenoic acid, ketoconazole, and inhibitors
like PEITC with the protein binding site. This is the first line of evaluation to determine what
type of compounds and their analogues binds favorably to the protein, which is a precursor to
determining the characteristic nature of that active site and by extension the protein itself. This
ultimately helps to elucidate the structure-function relationship of that protein.
To do this, 750µL of 1 µM protein fraction is added into 2 cuvettes: representing
reference and sample. Both cuvettes are placed in UV-VIS and the wavelength scan is set from
500nm to 350nm. CYP4X1 protein (4.1uM) obtained from affinity column is converted to 1 mM
using the formula: (750L) (1µM) = X µL (4.1µM). Then resuspension buffer amount used for
dilution is 750 µL minus X µL Then the amount of stock (X) to add to sample cuvette is
calculated by using the following formula: (0.5µM) (750µM) = (500µM stock) (X µL).
Same volume of ethanol is added to the reference cuvette. A 7-minute wait is observed
before running each sample after the addition of varied and calculated amount of substrate
(ligand) and reference (ethanol) to allow time for protein and ligand to bind.
This experiment is carried out until the observable peak and trough spectral shift in the
UV-VIS spectra becomes uniform. The binding affinity data obtained is evaluated using Prism8
software.
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CHAPTER 3 - RESULTS

This research involved attempts in elucidating the structure of CYP4X1 which is a
finicky membrane protein. Data reported here are from optimized protein expression protocols
for CYP4X1, narrative and pictorial representation of protein extraction and purification progress
using several column chromatography techniques. We measured the absolute protein content and
carbon monoxide difference assay via UV-VIS to show the concentration of active protein. We
then used the purified protein for substrate binding assays and to screen for crystal hits.
However, a significant portion of the results came from the optimization of expression protocols
for CYP4X1 in E. coli JM 109 cells and the associated purification. Vectors used to accomplish
cell transformation with CYP4X1 gene was alternated between two plasmids, pET28a and pCW.

3.1 Protein Expression and Purification
Preparing and autoclaving growth media and buffers like lysogenic broth, terrific broth as
well as phosphate buffers preceded any inoculation for starter culture or Protein expression
attempt. The first attempt on CYP4X1 Protein expression was with the pET28a vector purchased
with the codon optimized CYP4X1 gene into JM109 cells in pre-prepared glycerol stock. The
goal then was to translate it into proteins via induction with IPTG of E. coli JM109 cells. A
starter culture was initiated. 10µl of the glycerol stock was pipetted into autoclaved 100 ml LB
media, then 100 µl of antibiotic stock (50 mg/ml kanamycin) was added and the mixture was
shaken overnight in an incubator at 180 rpm and 37°C. The starter culture shown in Figure 3
gave excellent turbidity demonstrating good bacterial growth.
25

.
Figure 3: Starter culture for CYP4X1.

25 ml each of the overnight starter culture was split equally between 2 liters of TB media
for cell growth scale up. This was followed by the addition of 100 ml of potassium phosphate
solution and 1 ml of 50 mg/ml kanamycin sulfate (antibiotic stock) solution to each 1-liter TB
media. The cells were allowed a 2-hour timeline to grow, thereby allowing for an applicable
phase of cell increase before it is induced for optimum protein yield using isopropyl β- d-1thiogalactopyranoside (IPTG) and delta-aminolaevulinic acid (ALA). After a further two-day
cell growth at 32 ℃, the protein expressing bacterial cells were harvested by centrifugation at
6000 rpm and showed an incorporated heme cofactor evident by a characteristic brick-red
coloration.
After harvest, the pelleted cells were mixed in a resuspension buffer (1M Tris pH 8.0). To
break the cells for access to the membrane protein, the resuspended pellet was sonicated on ice
for 30 seconds at 80 percent with 30 second breaks three times. This was followed by membrane
protein extraction via proprietary detergent (Cymal-5) which gave a reassuring brick red
coloration. After stirring with detergent for 1-hour, solubilized protein was isolated by
centrifuging at 20,000 rpm for 20 minutes. This was quickly followed by double
chromatographic purifications via cobalt affinity and ion-exchange columns.
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The CYP450 protein yield was not pure as the 280nm peaks is saturated. SDS-PAGE gel
images illustrated in Figure 6 show lack of clean identifiable single bands at 50kDa despite
applications of two gravity-based column chromatography purifications. This is possibly due to
the presence of other macromolecules. Perhaps size exclusion column matrix would have
significantly helped in the purification. Most of the applicable protein possibly came off the
cobalt matrix in the wash phase or prior due to the deep red color obtained in the collected
fractions.

kDa
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70

63
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20
17
11

Figure 6: Electrophoretic gel of pET28a CYP4X1; Left-to right shows bands for protein ladder,
flowthrough, rinse, wash phase and elution fractions from the cobalt affinity column.
3.1.1 A second protein expression. The experiment was repeated with modifications to
the purification protocols. The lysate was run through serial column chromatography
purifications; this time with a newly acquired Bio-Rad biologic LP autosampler and fraction
collector. Also, the wash phase and elution from the cobalt (cobalt beads) affinity purification
were combined prior to the start of ion-exchange purification. Eluates (wash and elution) from
affinity column purifications was subjected to 10 times dilution with ion exchange wash buffer.
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This was followed by the addition of 0.2057g Cymal-5 detergent; although, it should have been
0.2374g based on the volume of the combined cobalt column protein wash and elution fractions;
there was not enough detergent at the time. Extraction detergent (Cymal-5) was added to the
sample mixture to prevent crashing of target membrane proteins on ion-exchange column matrix
and to aid with elution. Fractions of the ion exchange flowthrough and elution and cobalt rinse,
wash and elution were collected and analyzed by SDS-PAGE. Upon investigation of stained gel
using Coomassie blue, the SDS-PAGE purity check came out no identifiable CYP450 bands at
50kDa.
3.1.2 Change to pCW vector. A vector change was adopted for the third Protein
expression attempt, A new glycerol stock carrying the CYP4X1 gene cloned into pCW. The
antibiotic stock was also changed to ampicillin (50 mg/ml) from kanamycin sulfate because
pCW carries the ampicillin resistance gene. Obtained cell pellets showed a coffee-brown
coloration upon harvest at 6000 rpm, which was not expected as the previous brick red coloration
was anticipated. As a result, it could be inferred that either the pCW vector did not properly
translate the encode gene for the heme-thiolate prosthetic group or the polynucleotide sequence
is erroneously put together during gene construct.
3.1.3 The third protein expression and purification. Experimental trial was executed to
the end with membrane protein extraction and cobalt affinity column purification only.
Purification results obtained showed that most of the proteins eluted at the wash stage and
practically no protein was obtained from the elution. This was ascertained upon protein absolute
spectra analysis. SDS-PAGE analysis of collected affinity column fractions came out negative
for the target protein (CYP450). No ion-exchange purification was conducted. It was surmised
that perhaps the cells were not within the right optical density range before induction.
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The cells were initially allotted a 2-hour time lapse at 37℃ to accommodate for the appropriate
stage of growth without intermittently checking for an optimal OD 600 absorption value range of
0.4 -1.2.
3.1.4 The fourth protein expression and purification. Executed protocol adjusted for a
OD600 > 0.4 for the grown cells as recommended in related literature (Stark, Dostalek and
Guengerich, 2008). Also, a fresh colony was selected after DNA transformation instead of a
glycerol stock approach.
For the DNA transformation, E. coli JM109 cells in Eppendorf tubes were thawed on ice.
1 µL pCW vector carrying the target gene was aliquoted into the cells. The resulting mixture was
left on ice for 30 mins then placed in warm water at 37℃ for 35 seconds to heat shock cells. The
mixture was returned on ice for 2 minutes; giving the cells a chance to recover. 50µL of the
transformed cells were place at the center of LB-agar culture plates; glass beads were added to
spread the cells across the agar containing plates before being safely discarded. The plates were
incubated overnight at 37℃.
Using a pipette tip, a single colony of transformed cells was selected and emptied into
100ml of autoclaved LB media before incubating overnight at 37℃ and 180 rpm. The sample
which is the starter culture showed excellent turbidity. The rest of the experimental attempt
followed previous Protein expression protocols. The OD600 was at 0.44 before induction. Still,
the harvested cell pellets gave a coffee-brown coloration as shown in Figure 7.
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Figure 7: Images from pCW4X1 protein expression process. From left to right, culture plates after
transformation via heat shock, JM109 cell pellets showing coffee brown color instead of brick red
after harvest via centrifugation, pelleted cells homogenized in resuspension buffer.

Interestingly, the anticipated heme-thiolate color improved slightly upon detergent
extraction on ice as shown in Figure 8. This corroborates the impact of Cymal-5 on membrane
protein extraction.

Figure 8: Detergent extraction via cymal-5 for pCW4X1
This purification followed the same basic protocol as the first purification, the lysate after
centrifugation was purified by affinity and ion-exchange purification protocols with fractions
collected. Afterwards, a UV-VIS spectrophotometric analysis of elution ensued for absolute
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protein and carbon monoxide difference assay. A peak at around 400nm, which is customary to
CYP450 was obtained for the protein’s absolute spectrum. This validates the presence of heme in
the lysate solution containing CYP 4X1.
Typically, proteins carrying a heme cofactor have peaks around 400 nm while proteins
carrying amino acids like tryptophan, tyrosine and phenylalanine in their sequence give peaks
around 280nm. CYP4X1 being a characteristic cytochrome P450 meet both criteria.
Thus, from the spectra below, closer to 1:1 ratio of 400 nm peak to 280 nm peak indicates
increased purity of CYP4X1 protein. (Ortiz de Montellano, 2015).
The pCW CYP 4X1 protein was much purer due to the additional ion exchange
purification step using Bio-Rad biologic LP autosampler and fraction collector. Figure 9 below
illustrates this. When compared to gravity, the application of low solvent pressure via the
autosampler and fraction collector increases accuracy, integrity and overall resolution of
chromatogram peaks due to better interaction between the solubilized protein and the stationary
phase matrix.

Heme peak near 280 nm

Heme peak near 400 nm

Figure 9: UV-VIS spectrum of purified pCW CYP4X1 following ion exchange.
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3.1.5 The fifth protein expression. Experimental attempt was initiated but this time
doubling the volume E. coli cells inoculated. The cells pellets obtained after harvest was still
coffee-brown in coloration and the general results largely the same. The concentration of the
obtained protein was too low for characterization.
3.1.6 Return to pET28a plasmid. As a result of purification successes with the pCW
vector derived protein, but with very low yields, a decision was made to return to the pET28a
vector which seemed like it had better expression levels of CYP4X1.
3.1.7 The sixth protein expression. Experimental attempt involved a return to pET28a
plasmid carrying CYP4X1 into JM109 E. Coli cells in a glycerol stock. Ample OD600 range of
0.4- 0.8 prior to induction was also maintained. The expression protocol yielded cell pellets with
characteristic brick red (reddish brown) coloration upon harvest. This purification attempt of
these cells included experimental tweaks to optimize for obtaining the quantity and quality of the
membrane protein. The protocol change began with lysate acquisition via centrifugation
following sonication of cell pellets and detergent extraction of membrane proteins. The cold
centrifuge was increased from 15,000 rpm for 20 mins to 19,000 rpm for 20 mins. Increase in
rpm yielded a thick, slimy, deep red lysate previously unattained.
The lysate in this experimental attempt had much better overall consistency and richness
compared to those from previous protocol. Affinity chromatographic column via Bio-Rad LP
autosampler and fraction collected was initiated using nickel beads instead of cobalt. This switch
was made following an observation of another graduate student with a different protein that their
protein bound to a nickel affinity column but not a cobalt affinity column, which was previously
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used because His-tagged proteins have been reported to be purified with higher purity with
cobalt beads.
Just like in the lysate as explained in the methods chapter, Cymal-5 detergents were also
added to affinity column purification buffers in the following details:
-

Buffer A (Resuspension buffer) - 60 ml x 3.2mM X 494.5g/mol = 94944 / 1000ml /1000 =
0.095g of Cymal-5 added.

-

Buffer B (Wash buffer) - 40 ml x 3.2mM X 494.5g/mol = 63296 /1000ml /1000 = 0.063g of
Cymal-5 added.

-

Buffer C (Elution buffer) - 30 ml x 3.2mM X 494.5g/mol = 47472 /1000ml /1000 = 0.047g
of Cymal-5 added.
CYP4X1 did not make it to the wash phase as protein was not binding to the nickel beads

enough to create retention. Targeted protein was simply rinsed out of column upon the addition
of resuspension buffer. Absolute protein spectra of column rinse showed an absorbance peak at
406 nm which is around 400nm with no corresponding (parallel) peak around 300nm.
This demonstrates lack of purity The protein concentration calculated using Beer-Lambert’s
equation to obtain a decent 22.8 mM. Carbon monoxide difference assay did not indicate the
presence of active protein. SDS-PAGE-stained gel gave unusable bands across the purification
eluates.
3.1.8 The seventh attempt on protein expression. pET28a was used with a core focus
on optimizing nickel affinity purification. Although, this time the harvest for cell pellets was
centrifuged twice at 5000 rpm. Also, centrifugation of detergent extracted protein was set at
19000 rpm for 20 min to obtain cleaner lysate. Lysate was subjected to nickel-based affinity
column chromatography. Initial results show significant target protein coming off the wash
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I carried out absolute protein assay, carbon monoxide difference assay and SDS-PAGE
on both nickel affinity and ion-exchange eluates. UV-VIS’s data obtained for protein absolute
spectra showed an absorbance peak of 2.554 around 400nm. Obtained protein concentration
using Beer-Lambert’s equation yielded a value of 25.54 µM which is good. However, the protein
lacks optimum purity evident by the lack of a peak around 280nm in Figure 13.

Absorbance

Heme peak near 400 nm

Figure 13: Absolute protein spectrum from the seventh purification protocol.

I tested for the presence of active protein after bubbling carbon monoxide into Ni-NTA
column wash eluate and observed the characteristic right shift towards 450nm in Figure 14.
Absorbance value was 0.142 and a corresponding concentration value of 1.56 µM which is
considerably less than the total amount of protein present.
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Figure 14: Carbon monoxide difference spectrum from the seventh purification.

Absolute protein spectrum from Figure 15 below illustrates lack of pure protein after
carboxymethyl column purification.

Absorbance

Heme peak near 400 nm

Figure 15: Absolute protein spectrum from CM column.

Carbon monoxide difference spectrum in Figure 16 shows the presence of active protein but low
concentration after carboxymethyl column purification.
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Figure 16 Carbon monoxide difference spectrum from CM column.

SDS-PAGE gel in Figure 17 below was badly stained and practically unusable.

Figure 17: Electrophoretic gel from the seventh purification protocol.

3.1.9 The eighth protein expression and purification. Experimental attempt at
characterization involved an increase in prepared growth media (terrific broth) used; from 2 liters
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to 3 Liters. The idea was to significantly increase the amount of obtainable transformed E. Coli
cells upon harvest. Experimental protocol was deployed smoothly until protein purification.
Instead of tris buffers which were used on all purifications before this one, phosphate-based
buffers were used. Unlike Tris, phosphate buffer mimics cellular pH environment near 7.4 better
without adverse effects to cellular processes. Protein loaded well with lysate forming a decent
ring around the Ni-NTA column evident in Figure 18. Data obtained from collected fractions
showed that most of the target protein came off in the wash phase. Perhaps, the six residue histag was not properly transcribed during protein expression. 1ml of the Ni-NTA column fractions
was preserved for gel electrophoresis. Tubes 63 to Tubes 75 representing 40 ml of wash phase
fraction from nickel affinity column was diluted up to 160 ml with 120 ml of ion-exchange wash
buffer. Cymal-5 was added to the diluted wash solutions for ion exchange column purification.

Figure 18: Pictures from the purification process. From left to right, pelleted cells after
centrifugation, lysed pelleted cells homogenized in resuspension buffer, centrifuged lysate
decanted after detergent extraction, banding present on the Ni-NTA affinity column after loading
protein.

I carried out absolute protein assay on Ni-NTA column eluates. Absorbance value obtained is
0.612 as shown in Figure 19 and a corresponding concentration of 6.12 µM was obtained.
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3.1.10 The ninth protein expression and purification. Experimental attempt followed
previous working protocols but used Triton X-100 and CHAPS detergent (3-((3cholamidopropyl) dimethylammonium)-1-propanesulfonate) as detergents for membrane protein
extraction. This zwitterionic detergent(s) proves useful for membrane protein solubilization
when it is important to maintain protein activity.
The extracted protein gave the best visible lysate obtained in the project thus far, judging
by the unprecedented brick-red coloration, thickness, and consistency. One-third of this
resuspended pellet (45ml) was subjected to chromatographic purifications while two-thirds were
kept for later purification. With a return to Tris base instead of phosphate for the purification
buffers; Triton X-100 and CHAPS were also included in the resuspension, wash and elution
buffers used in purification buffers instead of Cymal-5 as follows:
CHAPS = 0.5% = 1 x CMCL = 0.5g / 100 ml = w/v
Triton x -100 = 1 x 0.04 = 0.9 ml/ 45 ml = v/v
For example, 60 ml of resuspension buffer with phosphate:
0.25/100 ml x 60 ml = 0.15 g of chap’s detergent in 60 ml
(60ml) (0.04%) = 240 ml of Triton X-100 / 0.24 ml
Forty milliliters of wash buffer and 30 ml of elution buffer were also prepared using the
same calculation for detergent addition to resuspension buffer. For Ni-NTA column purification,
the lysate did not bind well to the nickel column despite giving the visibly consistent heme-based
reddish brown colored lysate which probably had something to do with the detergent (triton and
CHAPS) used for extraction and in the purification.
UV-VIS spectra analysis on absolute protein was best in the rinse giving peaks with an
absorbance value of 0.612 near 400nm as evident in Figure 21. The protein concentration was
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low with concentrations of 6.12µM. The affinity column rinse still showed the presence of active
proteins with a right shift towards 450nm when carbon monoxide was bubbled through it. Ion
exchange purification was not conducted as the purification was ended after Ni-NTA column.
Heme peak near 280nm

Heme peak near 400 nm

Figure 21: Absolute protein spectrum of Ni-NTA affinity rinse.

3.1.11 The tenth protein expression and purification. This experimental attempt used
Cymal-5 and CHAPS as detergents for membrane protein extraction while Triton X-100 was
discontinued. Every other pre purification parameter was maintained. Left over cell pellets from
the ninth purification which makes up two-thirds of the former harvest was subjected to lysis via
sonication on ice. This was followed by protein extraction was carried out on an ice bath for 1hour using Cymal-5 and CHAPS.
CHAPS = 0.5% = 1 X CMCL = 0.5g / 100 ml = w/v
Cymal-5 = (100ml x 3.2 x 494.5) / 1000 x 1000 = 0.158g / 100 ml = w/v
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The extracted protein was centrifuged at 19000 rpm for 20 mins. Cymal-5 was added to
the Ni-NTA column buffers. The tenth protein expression attempt gave much better affinity
column result than the ninth. However, the protein precipitated on the Ni-NTA column during
the wash phase. Wash and elution buffers were combined; 0.66g more imidazole was added to
the mixture to aid in the elution of the protein that precipitated on the Ni-NTA column.
45 ml of the wash phase eluate was diluted with 90ml of wash buffer. This is to adjust for
concentration of salt content present. Cymal-5 was also included. The ion exchange purification
results carried out were not great. Protein absolute spectra assay was conducted but results
obtained were not usable either.
3.1.12 The eleventh protein expression and purification. Experimental attempt saw the
application of a new gene construct of pCW 4X1. This was done to ameliorate the crashing of
protein on the affinity resin, improve on low protein yield while anticipating an increase in the
expression of the heme thiolate prosthetic group. A single colony from culture plates was
inoculated into LB media. Thirty-three milliliters each of the cloudy overnight starter culture was
aliquot into 3 liters of TB media.
1 ml of 50 mg/ml antibiotic (ampicillin sodium) stock was added and allowed to grow at
37°C with 180 rpm shaking. OD600 was at 0.5 after 3.5 hours. Induction using IPTG and ALA
was initiated, and the culture was allowed to grow at 32°C, 180rm for 3 days. The obtained
pellets upon harvest were still coffee-brown coloration. Protein extraction used Cymal-5 and
CHAPS again just like it in the ninth expression attempt. For eluates obtained from Ni-NTA
affinity purification, tubes 27-29 from the fraction collector was the elution with a light-yellow
coloration. Absolute protein spectra in Figure 22 were positive but very low and impure for the
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CYP 450 protein present. With an absorbance of 0.167 and a corresponding concentration of
1.67µM.

Heme peak near 280 nm

Heme peak near 400 nm

Figure 22: Absolute protein spectrum of Ni-NTA elution for pCW4X1.

The carbon monoxide difference assay was carried out for test protein activity, but the
UV-VIS spectrum is not included here because concentration was nonexistent. Eluates from NiNTA was repurified on second column (DEAE). Ni-NTA column elution representing 12 ml was
diluted 5 times to 60ml with 48ml ion exchange wash buffer and 0.076 g of Cymal-5. 50 ml of
ion-exchange wash buffer was made with 0.079g of Cymal-5 also, 30ml of ion-exchange elution
buffer was made with 0.047g of Cymal-5 added. For purification of Ni-NTA column purified
protein elution, ion exchange worked better with DEAE than CM beads. Absolute spectra of
elution from ion exchange purification were good. However, the concentration of the protein
upon carbon monoxide was too small. 15ml of the elution from ion exchange (DEAE Column)
was concentrated by spinning at 5000 rpm for 15 minutes. 2mL of concentrated protein was
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added to 750 µL of ion exchange elution buffer present in UV-VIS cuvette. Remeasuring the
absolute protein spectra in Figure 23 yielded an absorbance of 0.021 and a corresponding
concentration of 0.21µM at wavelength of 406nm. Obtained lysate was reconcentrated further
via a micro concentrator to 160µM with carbon monoxide difference assay shown in Figure 24.

Heme peak near 280 nm

Heme peak near 400 nm

Figure 23: Absolute protein spectrum of re-concentrated DEAE ion-exchange elution.

Figure 24: Carbon monoxide difference assay of reconcentrated DEAE elution.
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I initiated SDS-PAGE of column eluates as shown in Figure 25. Affinity and ion exchange
eluates showed excellent promise as the characteristic CYP450 band was clearly seen in the
SDS-PAGE gel.
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Figure 25: Electrophoretic gel showing bands for pCW4X1. Gel wells for eluates were as
follows: Ladder, Ni-NTA flowthrough, Ni-NTA affinity wash, Ni-NTA affinity elution.
Ion-exchange flowthrough, ion-exchange elution.

3.1.13 The twelfth protein expression and purification. Protocol involved a return to
pET28a vector and kanamycin antibiotic stock. 20µl of glycerol stock was inoculated into 200ml
LB media. The resulting starter culture was aliquot into 3 liters of TB media prepared for scaleup growth. The marked increase was done to significantly increase the amount of obtainable cell
growth and by extension CYP450 protein. OD600 was at 0.72 prior to induction. 0.127g Cymal-5
and 0.393 CHAPS was used for protein extraction and stirred on ice for 1 hour. Extracted protein
was centrifuged at 19000 rpm for 20 mins to obtain lysate. I subjected lysate to Ni-NTA column
purification using nickel beads.
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Figure 27: Absolute protein spectra from reconcentrated DEAE column (second) purification.
Concentration obtained was approximately 0.24µM.

3.1.14. The thirteenth protein expression and purification. In this experimental
attempt, CYP4X1 pET28a glycerol stock (10µl) was inoculated into autoclaved 100ml LB
media. Added 100 µl of antibiotic (kanamycin 50 mg/ml sulfate). Shook overnight at 37˚C at 180
rpm in the incubator. I initiated growth scale up by adding 33ml of starter culture to each 1-liter
TB media making 3 liter in total and added kanamycin antibiotic stock and optimize growth till
OD 600 of 1.24. To make inducing agent, 1.44g ALA with 0.72 g IPTG were all in 3ml distilled
H2O and one milliliter was distributed to each flask and left to grow for 3 days. Cultured cells
were poured into eight 400ml containers and centrifuged at 4200 rpm for 15 mins. Bacteria
pellets exhibited very brick red coloration.
E. coli pellets in resuspension buffer were lysed with sonication and subjected to Cymal5 protein extraction and stirred on ice for 1hour. Extracted protein was centrifuged at 19000 rpm
for 20 min. The lysate was retained, and I discarded the pellets. The lysate was subjected to NiNTA column chromatography.
The results showed protein precipitation on the nickel column with most of the CYP 4X1
protein eluting in the wash phase. The assertion was made based off retention peak vs time on
the Bio-Rad fraction monitor. The CM column representing the second purification column on
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wash eluates that came of the affinity column. Wash eluates were from tubes 19-22 for the nickel
affinity column representing about 30ml. Wash eluate was diluted 5 times with 120ml of wash
buffer and 0.1898 of Cymal-5 detergent. 35ml of ion-exchange elution and 55ml of wash was
also furnished with Cymal-5 based on established calculation. Eluates from the purification were
concentrated and tested for absolute protein spectra, carbon monoxide difference assay,
crystallography and SDS-PAGE analysis.
For absolute spectra at 400 nm, an absorbance of 2.145 was obtained and this yielded a
concentration of 21.45 µM. Carbon monoxide difference assay at 444 nm yielded a concentration
of 1.98µM for active protein which was significantly less than the concentration of absolute
protein yield. Figure 28 below shows electrophoretic gel of the 1.98µM active protein
concentration.
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Figure 28: Electrophoretic gel of 1.98µM pET28a CYP4X1. Right to left electrophoretic gel
bands showing protein ladder, Ni-NTA flowthrough, resuspension rinse, wash phase, CM
flowthrough, CM wash, CM elution near 50 kDa from 1.9 µM pET28a.

3.1.15. The Fourteenth protein expression and purification. Experimental attempt
yielded an excellent turbidity for starter culture and OD 600 of 0.95 before induction via ALA
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and IPTG. 3ml of IPTG and ALA mixture was aliquot into 3 liter of terrific broth and incubated
at 180rpm at 32c for 3 days. Harvested cells by emptying grown cells in eight 400ml containers.
Pelletized bacterial cells exhibited the requisite heme thiolate brick red coloration. I carried out
membrane protein extraction using Cymal-5 and centrifuged extracted protein at 19000 rpm for
20 minutes then the lysate was separated for chromatographic purification. Results from
purification was negatively impacted by protein precipitation on the Ni-NTA column.
However, a significant proportion of the target protein was obtained in the wash phase and no
ion exchange purification was conducted. Concentration of protein obtained after carbon
monoxide difference assay was practically nonexistent at -22.5µM. Thus, making it unsuitable
for binding affinity and crystal screening.
3.1.16 The fifteenth protein expression and purification. This experimental attempt
was carried out using a pET28a vector. 100µL of CYP4X1 glycerol stock was inoculated into
LB media and incubated overnight. The resultant starter culture obtained yielded sufficient
turbidity. Starter culture was aliquot in 3 liters of terrific broth for scaled up growth. Ensured
OD600 was 1.423 before induction for scaled up growth with IPTG and ALA. Scaled up E. coli
cells were harvested, lysed open through sonication to access membrane protein. This was
followed by protein extraction using Cymal-5 and CHAPS detergents for 1 hour on an ice bath.
Extracted protein was centrifuged at 19000 rpm for 20 mins. The supernatant which represents
the lysate was kept for chromatographic purification. The affinity column results were affected
by a significant drop in pH of the elution buffer used. The buffer used dropped pH due to its age
in storage. Absolute protein spectrum of wash phase eluate in Figure 29 yielded characteristic
peaks near 400 and 280 nm respectively. However, the peaks did not illustrate optimum purity
in a 1:1 fashion and as seen earlier in the project with the pCW4X1 combination. Concentration
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calculated from obtained absorbance near 400nm was 5.59µM while the spectrum from carbon
monoxide difference assay for active protein obtained in Figure 30 was very low at 0.05µM. No
further protein concentration or characterizations were carried out.

Heme peak near 280nm

Heme peak near 400 nm

Figure 29: Absolute protein spectrum from pET28a CYP4X1.

Figure 30: Carbon monoxide difference assay from pET28a CYP4X1.
52

The protein used for binding assays was obtained from experiments by a fellow graduate
student Mehwish Khokhar whom in collaboration with Dr DeVore successfully obtained an
optimum purified protein elution for the target membrane protein prior to binding affinity assays.
As evident in Figure 31. SDS-PAGE was conducted on the lysate elution obtained from that
experiment to ascertain purity.
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Figure 31: Electrophoretic gel of successful 4.1mM CYP4X1. Right to left protein ladder,
flowthrough, resuspension rinsate, wash phase and elution near 50 kDa from 4.1µM pET28a NiNTA purified protein obtained by Mehwish Khokhar and Dr DeVore’s purification endeavors.
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The bands near 50kDa looks unclean with multiple bands indicating the presence of other
proteins present. However, the presence of bands near 50kDa corroborates the presence of
CYP450 protein irrespective of concentration.

3.2 Substrate Binding Affinity Assays
Binding assays of potentially favorable compounds was conducted to test their affinity
for CYP4X1 protein. The end goal was to determine binding constants of known and unknown
substrates. The binding assays were conducted on 4.1µM CYP4X1 protein Ni-NTA elution
obtained from efforts by Mehwish Khokhar and Dr Natasha DeVore. This prep was purified
using Cymal-5 and tris buffers.
Obtaining substrates binding affinity results starts with a series of stoichiometric
calculations; this is needed to determine the applicable protein and ligand stock concentrations
required for the assay. A stepwise example is as follows:
Anandamide stock for 750µL cuvette volume:
For 1µM of CYP4X1:
(4.1µM) x (ZµL) = (1µM) x (750µL). Therefore, ZµL = 182.9µL.
So 182.9µL of purified CYP4X1 lysate is aliquot into 567.1 µL of elution buffer.
Anandamide stock (M.W 347.53g/mol)
10mg in 200µL of anandamide
10mg/200µL = 0.01g/0.0002L = 50g/L
Molarity = (50g/L) / (347.53g/mol) = 0.144 mol/L = 0.144 M = 144 mM.
For 1mM Anandamide Stock:
(1mM x 1 ml) / 144mM = 0.0069 ml = 6.9µL
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So 6.9µL of 1mM anandamide stock was aliquot into 993.1µL of ethanol.
For 0.5mM Anandamide Stock:
500µL of 1mM anandamide stock was aliquot into 500µL of ethanol. After the above
calculation, binding affinity assays were carried out by aliquoting 750µL of 1µM CYP4X1 into a
pair of UV-VIS cuvette. UV-VIS wavelength scan is set from 500nm – 350nm range. Then
ligand stock volume additions are calculated and added to the cuvette in a stepwise fashion as
shown below. Same calculated amount of 100% ethanol is also added to the reference cuvette.
For the assay, the UV-VIS spectrophotometer is used in a dual beam mode, where an equal
amount of ethanol is added to the reference cuvette and ligand is added to the sample cuvette.
Additions:
For 0.5µM increment; (0.5 µM x 750µL) = (500µM x ZµL); X = 0.750µL
For 1µM increment; (0.5µM x 750.75µL) = (500µM x ZµL); X = 0.751µL
For 2 µM increment; (1µM x 751.501µL) = (1000µM x ZµL); X = 1.50µL
There is a 7-minute wait time after every stock and ethanol addition before scanning for
absorbance. The volume addition of ligand stock goes on till the targeted molarity is reached.
Binding affinity assays were carried out for the following compounds arachidonic acid,
anandamide, ketoconazole, eicosapentaenoic acid, phenethyl isothiocyanate (PEITC) and the
results were as follows:
3.2.1 Arachidonic acid. Arachidonic acid has been reported to be a substrate of
CYP4X1. As a substrate, the binding spectrum shifts should ideally yield a soret peak at a
maximum wavelength of type 1 spectral shift (390 – 405 nm) and trough at 415 - 420 nm. (Ortiz
de Montellano, 2015). Binding assays of CYP4X1 with arachidonic acid was tried a total of four
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times with their spectral peaks and troughs shifts shown in Figure 32. Each time, the shifts were
inconsistent with what was expected from a published substrate.

A

C

B

D

Figure 32: Spectrum of arachidonic acid binding assays. Top left to bottom right showing spectra
images of peaks and troughs of arachidonic acid binding assay attempt A-D.
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Although none of these assays have the absorbance shifts expected for a literature
reported substrate; However, the saturation curve plots were fitted according to the peak or
trough present and plotted against the concentration of arachidonic acid added. Overall,
Absorbance versus concentration data points does not fit the expected binding saturation curve
due to poor quality. However, the curve trend is sigmoidal (S-shaped) and translates to the
moderate (cooperative) binding of arachidonic acid to the protein. See Figure 33 for summary of
binding saturation curves.
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Figure 33. A) Saturation curve plot for the first arachidonic binding assay. B) Saturation curve
plot for the third arachidonic acid binding assay. C) Saturation curve plot for the fourth
arachidonic acid binding assay. D) The absorbance value at 407 nm from trials 1, 3, and 4 that
were obtained at the same concentrations were averaged and plotted with standard deviation
shown as error bars. Concentration data points that were only measured in trial 2 were excluded.
The Kd is 1.98 µM arachidonic acid and the absorbance max is 0.2256. Overall, the average plot
does not fit due to poor quality of substrate binding.
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Using only peak heights, the saturation curve obtained was sigmoidal (S-shaped) while
data obtained for the ketoconazole binding assay at maximal absorbance of 430nm yielded a
dissociation constant (Kd) value of 3.22 µM for trial 2. Also, a Kd value of 11.5 µM upon
average of trial 2 and 3 at similar concentrations. Interestingly, Mehwish Khokhar’s binding
assay obtained at a different concentration values yielded a dissociation constant value of 2.1µM.
These results indicate moderate ketoconazole affinity to the protein.
However, it is crucial to note that the interpretation of dissociation constant value
depends on what area of biochemical research focus is laid; for example, 1µM could be reported
as high affinity in metabolism regulation or low in the design of antibodies. Figure 37 below
shows spectrum with peaks and troughs from ketoconazole binding assay.

Figure 37: Spectrum of second ketoconazole binding assay.
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3.2.3 Eicosapentaenoic Binding Assay. For eicosapentaenoic acid, obtained binding
assay data shown in Figure 38 gave peaks and troughs with absorbance maximum at 400nm only
This is indicative of the presence of free heme in solution. Substrate is clearly not binding to the
protein.

Figure 38: Spectrum of eicosapentenoic binding assay.

3.2.4 PEITC (Inhibitor) Binding Assay. Phenethyl isothiocyanate (PEITC) is an
inhibitor with extensive (published) application in human cancer prevention. However, binding
assay spectrum data obtained and shown in Figure 39 yielded unrecognizable sites of peak
heights or trough for this potential inhibitor. The soret peaks and troughs at absorbance
maximum obtained was at 465nm and 400nm wavelength respectively. The binding spectrum
shifts should ideally yield a soret peak at a maximum wavelength of 425 nm – 435 nm and
trough at 390 - 405 nm (Ortiz de Montellano, 2015).
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Figure 39: Spectrum of PEITC binding assay.

3.3 Crystal screening for setups
Crystal screening was made from the concentrated 160µM purified protein obtained from
the twelfth CYP4X1 Protein Expression and purification experiment. Obtained image represents
initial crystals hits from commercial screens which is an indicative milestone and a guide for
future crystal optimization. Well B-12 from screening plates showed great potential with dark
spots that could lead to crystals observed under the microscope as shown in Figure 40.

Figure 40: Crystals of CYP4X1.
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CHAPTER 4 - DISCUSSION AND CONCLUSION

4.1 Discussion
The goal for this project as mentioned in the experimental design was to express the
CYP4X1 gene in E. coli JM109 cell using either pCW or pET28a vector. Purifying the resulting
protein and characterizing it primarily via substrate binding affinity assays. Lastly, a crystal
screen is performed to determine the crystallization condition of CYP4X1 after the protein is
optimally purified. Further optimization will be required in future experiments on this project
before 3-D structure can be considered and obtained via X-ray crystallography.
Glycerol stock from previous research endeavors and from a new gene construct was
mostly used to initiate experimental protocol on this project. Occasional cell transformation on
culture plates was required particularly when using pCW vector. Application of antibiotic stock
solution was an effective way to ensure the growth of targeted cells after cell transformation; as
E. coli Jm109 cells transformed via pET28a were designed to be immune to kanamycin sulfate
while cells transformed via pCW vector were designed to be immune to ampicillin during gene
construct. Overall, E. coli Jm109 cells showed excellent turbidity after inoculation irrespective of
what vector system was used, provided the right antibiotic stock was applied. This is an excellent
sign of E. coli Jm109 cell growth.
Evaluation of CYP4X1 over the course of 15 protein expression attempts showed that
when compared to pCW, the pET vector system delivered on a better yield in terms of
concentration of active protein and signature heme thiolate brick red coloration, it was also the
most adopted (11 times) in experimental trials. because from earlier data, it was the better of t2vector system implemented for the cloning and expression of my recombinant protein in
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E. coli. Consistent coffee brown coloration of harvested cells upon protein expression using pCW demonstrated lack of optimum
efficacy of that vector; especially in the expression of the functionally pivotal heme-thiolate prosthetic group.
Obtaining purified and significant molar concentration of CYP4X1 protein from expression endeavors was critically important
prior to characterization; but the experimental outcomes delivered a shortfall in reaching this objective. However, failed attempts,
successes, vectors used, issues encountered, corrections and tweaks made in CYP4X1 protein expression is summarized in Table 2.

Table 2: Summary of protein expressions and purifications.
Attempt Vector Expression and/or Assay Results

SDS-PAGE Outcome

Purification Observation

Corrections

First

Use LP Bio-Rad
UV-VIS analysis yielded a 400 nm heme Coomassie stained gel gave multiple
Protein eluted from cobalt
autosampler and fraction
pET28a peak. However, soret peak near 280nm horizontal bands near 50kDa upon SDScolumn matrix in the wash phase collector instead of gravity
was saturated upon protein assay
PAGE
for purifications

Second

Soret peaks obtained via UV-VIS
analysis indicate suboptimal yield for
pET28a
No identifiable single bands near 50kDa
CYP4X1. judging by 280nm and 410nm
peak ratio upon protein assay

Third

pCW

Protein eluted from cobalt
column matrix mostly in the
wash phase and some in the
elution

Coffee brown coloration of bacterial cell
pellets indicates poor expression of the
heme-thiolate prosthetic group. Obtained
Protein eluted from cobalt
No identifiable single bands near 50kDa
protein absorbance was not workable due
column matrix in the wash phase
to an unrecognized elevated spectral
shift.
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Vector was changed to pCW

Ensured optimal OD600
between 0.4 -1.2 from here
on out and repeated
experiment with the same
protocol Nil

Table 2, Continued.
Attempt Vector Expression and/or Assay Results

SDS-PAGE Outcome

Purification Observation

Corrections

Fourth

pCW

Coffee brown color persists of bacterial
pellets persists, but protein assay yielded
Positive single horizontal bands obtained Protein was purer due to the
Nil
spectrum with 1:1 soret peak ratio near
near 50kDa
addition of ion-exchange column
410 nm and 280nm respectively.
Indicating good yield.

Fifth

pCW

Coffee-brown coloration of bacterial cell
Return to pET28a vector and
Protein was purer due to the
pellets persists. Protein concentration was Positive single bands obtained near 50kDa
Ni-NTA beads for
addition of ion-exchange column
too low despite good yield.
purification

Sixth

Protein concentration from Ni-NTA
rinsate was at 22.8µM after assay.
pET28a
Carbon monoxide difference assay did
not yield active protein.

Seventh

Eight

CYP4X1 did not make it to the
Repeat the sixth
wash phase as protein did not
experimental protocol
bind well to the Ni-NTA column

Nil

Marked increase in prepared
Lysate crashed on the Ni-NTA growth media (terrific broth)
column. Significant protein came used; from 2 liters to 3 Liters
Protein concentration from Ni-NTA
off the Ni-NTA column in the from here on out. The idea
column elution was at 25.54 mM after
wash phase. Attempts to elute was to significantly increase
assay. However, the protein was not of
SDS-PAGE gel was unusable with
purified protein with increased the amount of obtainable
pET28a optimum yield evident by the peak
untraceable bands
concentration of imidazole
transformed E. Coli cells
around 280nm being saturated.
concentration yielded no positive upon harvest. Also, instead
Concentration of active protein after CO
outcome. Wash phase was
of tris buffers which were
difference assay was 1.42µM
subjected to additional CM (ion used on all purifications
exchange) purification.
before this one, phosphatebased buffers were used.
Protein loaded well with lysate Cymal-5 detergent was
Gel disintegrated during Coomassie
forming a decent ring around the combined with for membrane
Protein concentration obtained from
solution staining. Bands barely show any affinity column. Data obtained protein extraction. Unlike
pET28a assay after Ni-NTA eluates (wash plus
protein of interest. No identifiable single from collected fractions showed previous expression and
elution) was 6.12µM.
purification protocol that used
bands near 50kDa
that most of the target protein
CHAPS only.
came off in the wash phase.
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Table 2, Continued.
Attempt Vector Expression and/or Assay Results SDS-PAGE Outcome

Ninth

Triton and CHAPS detergent was used
for protein extraction. Detergent
combination yielded the best lysate
pET28a obtained thus far. Concentration of
Nil
protein obtained after assay was 6.12µM
which is too slow. Even before assay for
active protein is carried out

Tenth

pET28a

Eleventh pCW

Twelfth

CHAPS and Cymal used for protein
extraction

Unfortunately, Lysate did not
bind well to the Ni-NTA column
despite being the most visible
consistent brick-red coloration
obtained
Protein precipitated on the
NiNTA column

Nil

Impure and low concentration of purified
Multiple horizontal bands near 50kDa
protein which was too low for
upon Coomassie stained gel inspection.
characterization

Purified protein concentration was too
pET28a low for binding assays but yielded crystal Nil
hits in well B12.

Concentration of active protein
was1.98µM which is lower than the
Thirteenth pET28a
4.1µM eventually used for binding
assays.
Nonexistent active protein after CO
Fourteenth pET28a
difference assay.
Concentration of absolute protein was
5.59µM after assay. Active protein
Fifteenth pET28a concentration obtained (0.05µM) after
CO difference assay was too low. Not
suitable for binding assays.

Purification Observation Corrections

Protein eluted from NiNTA
column in the wash phase
fractions.
Protein eluted from NiNTA
column in the wash phase
fractions.

Triton X-100 and CHAPS
detergent were used during
membrane protein extraction
and solubilization.
Cymal-5 and CHAPS
detergent were used during
membrane protein extraction.
A return to Triton X-100 and
CHAPS detergent
combination for membrane
protein extraction and
solubilization
Used Cymal-5 Only as
detergent for extraction and
solubilization. Returned to
pET28a vector

Multiple horizontal bands near 50kDa
upon Coomassie stained gel inspection.

Protein precipitated on the
NiNTA column

No Change in Experimental
Protocol

Nil

Protein precipitated on the
NiNTA column

No Change in Experimental
Protocol

Nil

Protein eluted from NiNTA
column in the wash phase
fractions.

No Change in Experimental
Protocol
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After obtaining optimal protein yield was binding assay. Binding assays of potentially
favorable compounds like arachidonic acid, anandamide, ketoconazole, eicosapentaenoic and
PEITC were conducted to test their affinity on CYP4X1 protein and to determine which
compound from the available group of substrates have the potential for protein active site target.
A 4.1µM CYP4X1 protein obtained from Mehwish Khokhar’s purification attempt was assessed
for purity via SDS-PAGE and utilized for binding assays.
For arachidonic acid, the trend of absorbance against concentration showed moderate
binding to the CYP4X1 protein judging by the average saturation curve with a dissociation
constant, Kd value of 1.98µM (Figure 33, Section D). For anandamide, the compound shows no
real ligand binding for this endogenous cannabinoid (Figure 34).
For ketoconazole however, the results obtained for the second set of binding assays
indicated moderate ligand affinity to the CYP4X1 protein. The data points somewhat follow the
saturation curve with a dissociation constant (Kd) value of 3.22 µM when incorporating only
peak heights and 9.06 µM upon absolute difference between peaks and troughs. Ideally, the
lower the Kd value, the better the substrate binding potential. The Kd value quantifies the
equilibrium between the free ligand in solution and binding to a site in the protein (Figure 36).
For eicosapentaenoic acid binding assay, the data obtained gave peaks and troughs with
absorbance maximum at 400nm. This is indicative of the presence of free heme in solution;
Thus, the substrate is clearly not binding to the actual protein (Figure 38). For PEITC (Inhibitor)
binding assay, the soret peaks and troughs at absorbance maximum obtained were at 465nm and
400nm wavelength respectively. However, binding assay data obtained yielded unrecognizable
sites of peak heights or trough for this potential inhibitor (Figure 39).
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4.2 Conclusion
A total of fifteen protein expression and purification protocols were conducted to obtain
enough concentration to characterize the CYP4X1 protein via a series of binding affinity assays
and crystal structure determination. CYP4X1 gene were expressed successfully in E. coli using
pET28a and pCW vectors. Results obtained from expression attempts showed that pET28a
vector yielded more functional CYP4X1 protein evident by the appearance of heme thiolate
coloration and a series of much better CYP4X1 protein concentration yields.
In the thirteenth trial of protein expression and purification experiments, a 1.98 µM active
CYP4X1 protein was obtained via pET28a vector. Albeit it was a 0.24 µM active CYP4X1
protein obtained in the twelfth experimental trial (also via pET28a vector) that resulted in dark
spots and crystal hits during a commercial screening for crystallization conditions with further
optimizations required. However, the volume of both the 1.98µM and 0.24 µM active CYP4X1
protein was just too low for substrate binding assays.
Eventually, an optimally purified and metabolically active 4.1µM CYP4X1 from a
research associate’s experiment was eventually used for substrate binding assays due to the
better yield quality. The binding assay of substrates do not tell us about the functional active sites
of the target protein but rather gives an indication of the potential for certain biologically
favorable compounds and their analogs to affix suitably. Thus, giving guidance for future
characterization methods that could lead to active sites discovery of the three-dimensional
structure of the protein. Amongst the range of compounds assayed, arachidonic acid and
ketoconazole have demonstrated to be relatively cooperative compounds yet with moderate
substrate binding to the CYP4X1 protein. This conclusion was reached using dissociation
constants (from prism 8 software) obtained from average absorbance values of multiple trials at
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similar concentrations and plotted with standard deviation shown as error bars. Substrates like
arachidonic acid and ketoconazole with their Kd values clearly indicates the cooperative
tendency of these molecules to bind to the CYP4X1 protein. Same protein which now has a
crystal hit from the initial screening conditions (Figure 40).
Future work on this project may attempt to optimize the purity of the CYP4X1 protein
yield before characterization via a methodology that incorporates ketoconazole in the
purification buffers alongside Cymal-5 because it’s a good inhibitor. Alternatively, dialysis
technique can be adopted to reduce the impact of imidazole or to use alternatives to imidazole
found in literature. Imidazole has been reported to adversely influence crystallographic studies
and metabolic assays (Van Vugt-Van der Toorn, Dixon, & Vervoort, 2001). Lastly, other
substates may be tried for binding assays with purified CYP4X1.
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